Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Iberdomide (CC-220) for R/R myeloma: updated trial results

Sagar Lonial • 9 Dec 2019
ASH 2019
Multiple Myeloma Iberdomide

Sagar Lonial, MD, FACP, Winship Cancer Institute at Emory University, Atlanta, GA, discusses the the latest translational and clinical evidence for iberdomide (CC-220), a novel cereblon E3 ligase modulatory compound (CELMoD), from preclinical data and a current phase 1/2 trial in relapsed/refractory myeloma (NCT02773030). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Sagar Lonial

1:05
Real-world comparison of RVD vs D-RVD in newly diagnosed transplant-eligible multiple myeloma
Sagar Lonial • 9 Dec 2023
0:45
The addition of daratumumab to RVD deepens treatment responses in t(11;14) multiple myeloma
Sagar Lonial • 9 Dec 2023
1:06
DeRIVE trial update: DId vs DVd in newly diagnosed MM
Sagar Lonial • 9 Dec 2023
0:48
Final analysis of the DREAMM-2 trial: belantamab mafodotin for R/R multiple myeloma
Sagar Lonial • 7 Sep 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals